Searching for just a few words should be enough to get started. If you need to make more complex queries, use the tips below to guide you.
Article type: Research Article
Authors: Katisko, Kaspera; * | Krüger, Johannab; c | Soppela, Helmia | Hartikainen, Päivid | Haapasalo, Annakaisae | Remes, Anne M.b; c | Solje, Einoa; d
Affiliations: [a] Institute of Clinical Medicine – Neurology, University of Eastern Finland, Kuopio, Finland | [b] Research Unit of Clinical Medicine, Neurology, University of Oulu, Oulu, Finland | [c] MRC, Oulu University Hospital, Oulu, Finland | [d] Neuro Center – Neurology, Kuopio University Hospital, Kuopio, Finland | [e] A.I. Virtanen Institute for Molecular Sciences – University of Eastern Finland, Kuopio, Finland
Correspondence: [*] Correspondence to: Kasper Katisko, MD, PhD, University of Eastern Finland – Institute of Clinical Medicine, Neurology, P.O. Box 1627 (Yliopistonranta 1C) FI-70211 Kuopio, Finland. Tel.: +358 505956696; E-mail: [email protected].
Abstract: Background:Due to the significant presence of neuropsychiatric symptoms in patients with frontotemporal dementia (FTD) spectrum disorders, psychiatric misdiagnoses, diagnostic delay, and use of psychiatric treatments are common prior to the FTD diagnosis. Furthermore, treatment of diagnosed FTD patients mainly relies on off-label psychopharmacological approaches. Currently, limited real-world data are available regarding the actual use of psychopharmacological medications in FTD. Objective:To evaluate psychopharmacological medication use at the time of FTD diagnosis. Methods:Psychopharmacological medication use was evaluated in a Finnish FTD cohort containing 222 FTD patients, including the major clinical disease phenotypes (behavioral, language, and motor variants) and genetic patients carrying the C9orf72 repeat expansion. A cohort of 214 Alzheimer’s disease (AD) patients was used as a neurodegenerative disease reference group. Results:Active use of psychopharmacological medications at the time of diagnosis was significantly more common in FTD compared to AD, especially in the case of antidepressants (26.1% versus 15.0%, OR = 2.01, p = 0.008), antipsychotics (23.9% versus 9.3%, OR = 3.15, p < 0.001), and mood-stabilizers (6.3% versus 1.9%, OR = 2.93, p = 0.085; not statistically significant), whereas the use of cholinesterase inhibitors or memantine was nearly nonexistent in FTD patients. Female gender and behavioral variant of FTD phenotype alongside with depressive and psychotic symptoms were the most prominent factors associating with the use of these medications among the FTD spectrum patients. Conclusion:Use of off-label psychopharmacological medication and polypharmacy is substantially common at the time of FTD diagnosis. This likely reflects the challenges in using symptom-driven treatment approaches, especially prior to the eventual diagnosis.
Keywords: Alzheimer’s disease, frontotemporal dementia, pharmacology, psychiatry, psychopharmacology, therapeutics
DOI: 10.3233/JAD-230494
Journal: Journal of Alzheimer's Disease, vol. 95, no. 2, pp. 677-685, 2023
IOS Press, Inc.
6751 Tepper Drive
Clifton, VA 20124
USA
Tel: +1 703 830 6300
Fax: +1 703 830 2300
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
IOS Press
Nieuwe Hemweg 6B
1013 BG Amsterdam
The Netherlands
Tel: +31 20 688 3355
Fax: +31 20 687 0091
[email protected]
For editorial issues, permissions, book requests, submissions and proceedings, contact the Amsterdam office [email protected]
Inspirees International (China Office)
Ciyunsi Beili 207(CapitaLand), Bld 1, 7-901
100025, Beijing
China
Free service line: 400 661 8717
Fax: +86 10 8446 7947
[email protected]
For editorial issues, like the status of your submitted paper or proposals, write to [email protected]
如果您在出版方面需要帮助或有任何建, 件至: [email protected]